Foundations Investment Advisors LLC Buys 18,894 Shares of Novartis AG (NYSE:NVS)

Foundations Investment Advisors LLC lifted its stake in shares of Novartis AG (NYSE:NVS) by 26.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 89,074 shares of the company’s stock after purchasing an additional 18,894 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Novartis were worth $8,668,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Novartis by 115.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after acquiring an additional 124,111 shares during the last quarter. CWA Asset Management Group LLC increased its stake in Novartis by 20.1% in the 4th quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after acquiring an additional 5,164 shares during the last quarter. Quantbot Technologies LP increased its stake in Novartis by 135.5% in the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after acquiring an additional 22,998 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Novartis by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock worth $18,088,000 after purchasing an additional 18,990 shares in the last quarter. Finally, Natixis Advisors LLC boosted its holdings in Novartis by 2.9% during the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock valued at $107,986,000 after acquiring an additional 26,317 shares during the period. 13.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on NVS. BMO Capital Markets increased their price objective on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating and six have issued a hold rating to the company. According to data from MarketBeat, Novartis presently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Stock Up 2.3 %

NVS stock opened at $102.29 on Monday. The firm has a market cap of $209.08 billion, a PE ratio of 11.89, a price-to-earnings-growth ratio of 1.42 and a beta of 0.57. The business has a 50 day moving average of $100.09 and a 200 day moving average of $108.69. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same quarter last year, the company earned $1.74 EPS. On average, research analysts forecast that Novartis AG will post 7.62 EPS for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.